Open Access

Prevalence and correlates of proteinuria in Kampala, Uganda: a cross-sectional pilot study

  • Joseph Lunyera1, 2Email author,
  • John W. Stanifer3,
  • Prossie Ingabire4,
  • Wilson Etolu4,
  • Peace Bagasha4,
  • Joseph R. Egger1,
  • Uptal D. Patel3, 5,
  • Gerald Mutungi6 and
  • Robert Kalyesubula4, 7
Contributed equally
BMC Research Notes20169:97

https://doi.org/10.1186/s13104-016-1897-6

Received: 2 December 2015

Accepted: 1 February 2016

Published: 16 February 2016

Abstract

Background

Despite the increasing prevalence of chronic kidney disease (CKD) in sub-Saharan Africa, few community-based screenings have been conducted in Uganda. Opportunities to improve the management of CKD in sub-Saharan Africa are limited by low awareness, inadequate access, poor recognition, and delayed presentation for clinical care. Therefore, the Uganda Kidney Foundation engaged key stakeholders in performing a screening event on World Kidney Day.

Methods

We conducted a cross-sectional pilot study in March 2013 from a convenience sample of adult, urban residents in Kampala, Uganda. We advertised the event using radio and television announcements, newspapers, billboards, and notice boards at public places, such as places of worship. Subsequently, we screened for proteinuria, hypertension, fasting glucose impairment, and obesity in a central and easily-accessible location.

Results

We enrolled 141 adults most of whom were female (57 %), young (64 %; 18–39 years), and had a professional occupation (52 %). The prevalence of proteinuria (13 %; 95 % confidence interval [CI] 7–19 %), hypertension (38 %; 95 % CI 31–47 %), and impaired fasting glucose (13 %; 95 % CI 9–20 %) were high in this study population. Proteinuria was most prevalent among young (18–39 years) adults (n = 14; 16 %) and among those who reported a history of alcohol intake (n = 10; 32 %).

Conclusions

The prevalence of proteinuria was high among a convenience sample of urban residents in a sub-Saharan African setting. These results represent an important effort by the Ugandan Kidney Foundation to increase awareness and recognition of CKD, and they will help formulate additional epidemiological studies on NCDs in Uganda which are urgently needed and now feasible.

Keywords

Proteinuria Kidney disease Epidemiology Uganda Non-communicable diseases Sub-Saharan Africa

Background

Chronic kidney disease (CKD) is a growing health burden globally, with many known and unknown etiologies [1]. In sub-Saharan Africa (SSA), the epidemiology of CKD has not been well described [2], and in Uganda, few community-based studies assessing kidney function have been conducted. Nonetheless, recent epidemiological studies in SSA suggest that the prevalence is substantial, with estimates as high as 24 % in Zambia and 15 % in some urban areas of Tanzania [27].

Opportunities to improve the management of CKD in SSA are limited by low awareness, inadequate access, poor recognition, and delayed presentation for clinical care [8]. As such, the morbidity and mortality from CKD are significant especially considering the lack of cardiovascular care and inadequate access to renal replacement therapies (RRT), such as peritoneal dialysis, hemodialysis, or kidney transplantation [9]. In Uganda, hemodialysis services are only available in limited urban centers (0.1 dialysis machine/100,000 population) and there are no active kidney transplant programs [9]. In 2011, kidney disease was the 13th most common cause of death in Uganda, with the estimated annual age-adjusted death rate attributable to CKD in Uganda (27.8 per 100,000 population) [10] exceeding the global estimate (16.3 per 100,000) [1].

Given the limited understanding of kidney disease in Uganda, the Uganda Kidney Foundation was founded on March 13th 2013 to advocate, increase awareness, and improve care for kidney disease in Uganda. To achieve this mission, demonstrating the feasibility of screening studies that can describe the epidemiology of kidney disease are urgently needed. Therefore, as part of the International Society of Nephrology World Kidney Day Campaign on March 13th 2013 in Kampala, we performed a community-based pilot study to raise awareness by assessing kidney function through proteinuria measurements.

Methods

Ethical approval

Ethical approval for this study was granted by the Mulago Hospital Ethical Review Board. Informed consent was obtained from all participants prior to their enrollment.

Study design, participants, and site

We conducted a cross-sectional pilot study in March 2013 from a convenience sample of adult (≥18 years old) urban residents in Kampala, Uganda. Kampala is the largest city in Uganda with a population of more than 1.5 million people [11]. Most residents belong to the Bantu ethnic group, but Nilotes and other ethnicities are also common [12].

Prior to the study, we advertised using radio and television announcements, newspapers, billboards, and noticeboards at public places, such as places of worship. The advertisements were designed to produce a study catchment area that included all the five divisions of Kampala [11]. To be eligible for the study, individuals had to be overnight fasting and report no prior medical history of kidney disease. We enrolled consecutive individuals who met these inclusion criteria. The study site was located on the campus of Makerere University College of Health Sciences (MakCHS), School of Medicine, which is located 3 km from the city center and is easily accessible.

Data collection

We collected socio-demographic characteristics from interviewer-administered surveys, as well as anthropometric and blood pressure measurements, random blood glucose (RBG) using a finger-prick glucose assay, and a mid-stream clean-catch urine for urine protein. Individuals who screened positive for disease were provided appropriate referral to Mulago Hospital for further clinical care.

For the anthropometric measurements, weight was measured in kilograms (kg) using a pre-calibrated weighing scale (Seca scale). Height was measured in centimeters (cm) using a standardized stadiometer. Body mass index (BMI) was calculated from the weight and height measurements for respondents as follows: BMI = (weight/height2). Overweight was defined as BMI between 25 and 30 kg/m2; obesity was defined as BMI ≥30 kg/m2.

Blood pressure was measured using automated sphygmomanometers that were calibrated according to the manufacturer’s recommendations. Blood pressure was measured after 10 min rest in a seated position. A second blood pressure measurement was taken at a minimum 5 min interval from the initial measurement. Systolic hypertension was defined as an average systolic blood pressure (SBP) ≥140 mmHg, and diastolic hypertension was defined as an average diastolic blood pressure (DBP) ≥90 mmHg. Hypertension was defined as the presence of systolic or diastolic hypertension, or on-going use of blood pressure lowering medicines among those with self-reported history of hypertension.

Finger-prick blood samples were obtained to measure random blood glucose using the Accu-Chek Active glucometer (Roche Diagnostics, Germany), which was calibrated according to the manufacturer’s recommendation. Fasting glucose impairment was defined as RBG >126 mg/dl, or on-going use of anti-diabetic medicines among those who reported having diabetes. Respondents also provided a clean-catch midstream urine specimen in sterile containers for a dipstick urinalysis (Combur Test M, Roche Diagnostics, Germany). Proteinuria was defined as a urine protein of ≥1+ on dipstick in the absence of hematuria and leukocyturia.

Statistical analysis

Data were manually entered into a Microsoft Excel spreadsheet. All entries were double-checked for accuracy by two independent study personnel, and then exported to STATA v.13 software (Stata corp., College Station, TX) for analyses. Continuous variables were summarized by their median and inter-quartile range (IQR) and categorical variables as crude counts and percentages. We estimated the crude, unweighted prevalence of proteinuria and other CKD co-morbidities with 95 % confidence intervals (CI). We used generalized linear models with a log link to report prevalence ratios (PR) and explore associations between proteinuria, hypertension, obesity, impaired fasting glucose, and socio demographic and lifestyle characteristics. A p value of <0.05 was considered statistically significant.

A secondary interest of the study was to identify high risk groups in the community. We estimated the potential benefit of screening among these high risk groups as the number needed to screen (NNS) in order to identify one case of proteinuria, which was defined as the reciprocal of the absolute risk reduction [13]. Using Bender’s method, we constructed a 95 % CI around the NNS estimates [14]. Confidence intervals were truncated at zero.

Results

Characteristics of study participants

We enrolled 141 adults, most of whom were female (n = 81; 57 %), 18–39 years of age (n = 87; 64 %), and had a professional occupation (n = 71; 52 %). Fewer than half reported a history of alcohol intake (n = 54; 39 %), and only two (1 %) reported a history of smoking. Few respondents had a self-reported medical history of hypertension (n = 21; 15 %), diabetes (n = 8; 6 %), or heart disease (n = 4; 3 %) (Table 1). These demographics were similar to the population of Kampala where most people are female (53 %) and 18–39 years of age (61 %), and where many people are occupied as wage earners (24 %), with few being unemployed (4 %) [11, 15].
Table 1

Characteristics of participants by proteinuria status (n = 141), Kampala, Uganda; 2013

Demographic and clinical characteristics

All, n = 141

With proteinuria, n = 18 (13 %)

Without proteinuria, n = 121 (87 %)

Crude PR (95 % CI)

Adjusted PRa (95 % CI)

Age

 18–39 years old

87

14 (16 %)

72 (84 %)

3.74 (0.89–15.77)

7.96 (1.39–45.44)

 40–59 years old

46

2 (4 %)

44 (96 %)

Ref

Ref

 ≥60 years old

4

0

4 (100 %)

Gender

 Male

60

9 (15 %)

50 (85 %)

1.36 (0.57–3.21)

 Female

81

9 (11 %)

71 (89 %)

Ref

Occupation

 Unemployed

6

1 (17 %)

5 (83 %)

Ref

 Student

27

2 (7 %)

25 (93 %)

 Wage earnerb

33

7 (21 %)

26 (79 %)

1.35 (0.30–6.10)

 Professionalc

71

7 (10 %)

63 (90 %)

2.25 (0.24–20.96)

History of Smoking

2

0

2 (100 %)

History of alcohol intake

54

11 (20 %)

43 (80 %)

2.44 (1.01–5.92)

3.92 (1.10–14.03)

 18–39 years old

31

10 (32 %)

21 (68 %)

4.35 (1.49–12.7)

 40–59 years old

20

1 (5 %)

19 (95 %)

1.30 (0.09–19.5)

 >60 years old

2

0

2 (100 %)

Self-reported medical history

 Hypertension

21

1 (5 %)

20 (95 %)

 Diabetes mellitus

8

2 (25 %)

6 (75 %)

 Heart diseased

4

0

4 (100 %)

Body mass index

 Normal weight

58

8 (14 %)

50 (86 %)

Ref

 Overweight

81

10 (12 %)

71 (88 %)

1.24 (0.49–3.14)

 Obese

40

3 (8 %)

37 (92 %)

0.54 (0.15–1.93)

Hypertension

54

9 (17 %)

45 (83 %)

1.57 (0.67–3.71)

1.50 (0.41–5.83)

 Systolic hypertension

38

8 (21 %)

30 (79 %)

2.13 (0.91–4.98)

 Diastolic hypertension

29

5 (17 %)

24 (83 %)

1.46 (0.57–3.76)

 Impaired fasting glucose

19

5 (26 %)

14 (74 %)

2.43 (0.98–6.04)

1.64 (0.28–9.73)

PR prevalence ratio

aCo-variates: gender, occupation, hypertension, impaired fasting glucose

bWage earner: any non-salaried position (e.g., construction worker, farmer)

cProfessional: any salaried position (e.g. nurse, teacher, government employee)

dHeart disease: coronary disease, heart failure, or structural diseases

The median BMI of respondents was 25.9 kg/m2 (IQR 22.7–30.7). More than half of respondents were overweight (n = 83; 59 %; 95 % CI 50–67 %) and many (n = 42; 30 %; 95 % CI 22–37 %) were obese. The median SBP was 128 (IQR 120–138) mmHg, and median DBP was 78 (IQR 71–85) mmHg. The prevalence of hypertension was 38 % (95 % CI 31–47 %). Among participants with hypertension (n = 54), systolic hypertension was more prevalent (27 %; 95 % CI 20–34 %) than diastolic hypertension (21 %; 95 % CI 14–27 %). The median random blood glucose for participants was 91 (IQR 80–105) mg/dl, and 19 (13 %; 95 % CI 9–20 %) participants had impaired fasting glucose. Eighteen participants (13 %; 95 % CI 7–19 %) had proteinuria, of whom 16 had proteinuria of 1+ (89 %) and 2 (11 %) had proteinuria ≥2+ (Table 1).

The majority of participants diagnosed with medical conditions during the screening were not aware of having these conditions. Of the 43 participants newly diagnosed with hypertension at the screening, most (n = 32; 74 %) were unaware of having hypertension, and of the 10 participants with impaired fasting glucose, most (n = 7; 70 %) were unaware.

Epidemiology of proteinuria, hypertension, and impaired fasting glucose

Proteinuria was most prevalent among young (18–39 years) adults (n = 14; 16 %), and it was more prominent in those who reported a history of alcohol intake (n = 10; 32 %). It was also most prevalent among adults with impaired fasting glucose (n = 3; 30 %), those who reported a history of diabetes (n = 2; 25 %), those with systolic hypertension (n = 8; 22 %), and those occupied as wage earner (n = 7; 21 %) (Table 1). There was no significant difference in the prevalence of proteinuria by gender. Proteinuria was less prevalent among participants with self reported medical history of hypertension (n = 1; 5 %), among older adults aged 40–59 years old (n = 2; 4 %) or ≥60 years old (n = 0), and among adults with self-reported history of smoking (n = 0) or heart disease (n = 0).

In univariable regression, self-reported history of alcohol intake (PR = 2.44; 1.01–5.92) and younger age (18–39 years old) (PR = 3.74, 0.89–15.77) were significantly associated with proteinuria. There was no significant association between proteinuria and impaired fasting glucose, hypertension, overweight, obesity, smoking, gender, or occupation (Table 1). When stratified by age, the significant association between alcohol intake and proteinuria was most prominent among younger (18–39 years) adults (PR = 4.35, 1.49–12.70). In multi-variable regression, the association between alcohol intake and proteinuria (PR = 3.92; 95 % CI 1.10–14.03) persisted despite adjustment for occupation, hypertension, and impaired fasting glucose.

Potential benefits of targeted screening for proteinuria

The number needed to screen in order to identify one case of proteinuria in this convenience sample of urban residents in Kampala was eight among young (18–39 years old) adults, six among young (18–39 years old) adults who were occupied as professionals, and four among young (18–39 years old) adults who had hypertension. Among adults who report a history of alcohol intake, the number needed to screen to identify one case of proteinuria was eight across all age groups, and four among young (18–39 years) adults.

Discussion

Our pilot study is one of the first to assess kidney function, fasting glucose impairment, hypertension, and obesity in a community setting in Uganda. The prevalence of proteinuria was high in this study population, and it was most prevalent among younger participants. Concurrent with this high prevalence was low disease awareness for hypertension and impaired fasting glucose.

Although non-communicable diseases (NCDs) such as diabetes and hypertension account for most cases of CKD in high-income countries [1], many recent studies in low- and middle-income countries (LMICs) have shown that CKD may only be partly attributable to these NCDs [6]. Other potential etiologies for CKD in LMICs include herbal medicines, environmental toxins, such as heavy metals and agrochemicals, as well as many other unmeasured factors [1, 6, 7, 16]. Our findings are consistent with these observations, and they highlight a need to explore potential etiologies of CKD, e.g., the role that alcohol or other environmental toxins may play in the development of proteinuria among young adults.

In LMICs, CKD affects younger portions of the population which reflects the different population demographics observed in these countries [1, 7, 8]. Our study, which found a significantly higher prevalence among younger age groups, highlights the urgent need for epidemiologic studies capable of identifying high-risk populations. Proteinuria is an important predictor of risk of progression to end-stage renal disease as well as cardiovascular disease [1719]. As such, understanding its epidemiology, especially if it disproportionately affects younger, economically productive adults, is critically important in developing public health agendas in Uganda. Moreover, because of the limited availability and readiness of the health system in Uganda to care for chronic diseases such as CKD [20], screening for proteinuria, which is an efficient, reliable, and easily obtainable means of assessing kidney function, may be an effective strategy, particularly in lower level health facilities where other kidney function measurements are not available [2123].

In response to the need for increasing awareness and screening for NCDs such as CKD, the Uganda Kidney Foundation has used various platforms and strategies to engage key stakeholders, such as physicians, nurses, medical officers, and public health officials in the Ministry of Health. The Uganda Kidney Foundation also partnered with professional societies including the International Society of Nephrology (ISN) to organize the first international kidney conference in Kampala in 2012 to increase awareness and care for kidney disease among clinicians [24]. Because CKD often goes undetected, collaborative efforts to increase awareness and to screen at-risk community members may be the most effective and cost-efficient public health strategies to address the burden of CKD, particularly in a LMIC like Uganda [2529].

Our study has many strengths. The screening activity was carried out by internal medicine residents at MakCHS, who obtained relevant medical history from respondents during the screening to exclude data from respondents with proteinuria secondary to other medical conditions, such as urinary tract infections (UTIs). Additionally, with limited resources, we were able to screen for proteinuria, hypertension, impaired fasting glucose, and obesity using standard definitions and diagnostic tests.

Despite these strengths, we noted several limitations. Because urine dipstick measurements for proteinuria can be non-specific, we could not exclude orthostatic or transient proteinuria, or evaluate for possible glomerulonephritis, and we did not repeat the proteinuria assessment. Additionally, we did not assess kidney function using serum creatinine and estimated glomerular filtration rate, and the cross-sectional design prevents any causal assumptions about etiologies. For example, the association between alcohol intake and proteinuria that we observed could be due to unmeasured confounding effects. Because we obtained a convenience sample of people who attended the World Kidney Day celebrations in Kampala, our prevalence estimates are not generalizable to the Kampala urban population. As such, our confidence intervals are intended to measure the variance of the observed sample, and not the underlying Kampala general population. Selection bias was also a concern. Health-conscious individuals were more likely to participate in screening activities than the general population. Nonetheless, our pilot findings highlight the urgent need for and feasibility of future epidemiological studies pertaining to CKD and other NCDs in Uganda.

Conclusions

We observed a high prevalence of proteinuria in a convenience sample of urban residents in a sub-Saharan African setting. These results are among the first to be reported for a community-based sample in Uganda, and they represent an important effort by the Uganda Kidney Foundation to increase awareness and recognition of CKD. These estimates will help formulate additional epidemiological studies on NCDs in Uganda which are urgently needed.

Notes

Declarations

Authors’ contributions

JL, RK, PB and PI conceived and designed the study. PB, PI and WE collected data for this study during the screening exercise. JL, JE, JWS and UDP analyzed the data. All authors participated in drafting the manuscript. All authors read and approved the final manuscript.

Acknowledgements

The authors would like to acknowledge the financial contributions by the Ministry of Health, Republic of Uganda & the Uganda Kidney Foundation, which made this study possible. We also thank the study respondents who willingly consented to participate in the study.

Competing interests

The authors declare that they have no competing interests.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Duke Global Health Institute, Duke University
(2)
School of Medicine, Makerere University College of Health Sciences
(3)
Department of Medicine, Duke Clinical Research Institute and Duke Global Health Institute, Duke University
(4)
Department of Medicine, Mulago Hospital, Makerere University College of Health Sciences
(5)
Departments of Medicine and Pediatrics, Duke Clinical Research Institute and Duke Global Health Institute, Duke University
(6)
Section of Non-communicable Diseases, Ministry of Health
(7)
Department of Physiology, Makerere University College of Health Sciences

References

  1. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, Saran R, Wang AY, Yang CW. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382:260–72.View ArticlePubMedGoogle Scholar
  2. Stanifer JW, Jing B, Tolan S, Helmke N, Mukerjee R, Naicker S, Patel U. The epidemiology of chronic kidney disease in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Glob Health. 2014;2:e174–81.View ArticlePubMedGoogle Scholar
  3. Wyatt CM, Shi Q, Novak JE, Hoover DR, Szczech L, Mugabo JS, Binagwaho A, Cohen M, Mutimura E, Anastos K. Prevalence of kidney disease in HIV-infected and uninfected Rwandan women. PLoS ONE. 2011;6(3):e18352.PubMed CentralView ArticlePubMedGoogle Scholar
  4. Rolfe M. Diabetic renal disease in central Africa. Diabet Med. 1988;5(7):630–3.View ArticlePubMedGoogle Scholar
  5. Mulenga LB, Kruse G, Lakhi S, Cantrell RA, Reid SE, Zulu I, Stringer EM, Krishnasami Z, Mwinga A, Saag MS, Stringer JS, Chi BH. Baseline renal insufficiency and risk of death among HIV-infected adults on antiretroviral therapy in Lusaka, Zambia. AIDS. 2008;22(14):1821–7.PubMed CentralView ArticlePubMedGoogle Scholar
  6. Stanifer JW, Maro V, Egger J, Karia F, Thielman N, Turner EL, Shimbi D, Kilaweh H, Matemu O, Patel UD. The epidemiology of chronic kidney disease in Northern Tanzania: a population-based survey. PLoS ONE. 2015;10(4):e0124506.PubMed CentralView ArticlePubMedGoogle Scholar
  7. Stanifer JW, Lunyera J, Boyd D, Karia F, Maro V, Omolo J, Patel UD. Traditional medicine practices among community members with chronic kidney disease in Northern Tanzania: an ethnomedical survey. BMC Nephrol. 2015;16(1):170.PubMed CentralView ArticlePubMedGoogle Scholar
  8. Kalyesubula R, Lunyera J, Makanga G, Kirenga B, Amukele TK. A 4-year survey of the spectrum of renal disease at a National Referral Hospital Outpatient Clinic in Uganda. Kidney Int. 2015;87(3):663.View ArticlePubMedGoogle Scholar
  9. Naicker S. End-stage renal disease in sub-Saharan Africa. Kidney Int. 2013;3:161–3.View ArticleGoogle Scholar
  10. Bagasha P, Nakwagala F, Kwizera A, Ssekasanvu E, Kalyesubula R. Acute kidney injury among adult patients with sepsis in a low-income country: clinical patterns and short-term outcomes. BMC Nephrol. 2015;16:4.PubMed CentralView ArticlePubMedGoogle Scholar
  11. Uganda Bureau of Statistics (UBOS). National Population and Housing Census 2014: Provisional Results. Kampala: UBOS; 2014.Google Scholar
  12. Kajumbula H, Wallace RG, Zong JC, et al. Ugandan kaposi’s sarcoma-associated herpesvirus phylogeny: evidence for cross-ethnic transmission of viral subtypes. Intervirology. 2006;49(3):133–43.View ArticlePubMedGoogle Scholar
  13. Richardson A. Screening and the number needed to treat. J Med Screen. 2001;8(3):125–7.View ArticlePubMedGoogle Scholar
  14. Bender R. Calculating confidence intervals for the number needed to treat. Control Clin Trials. 2001;22:102–10.View ArticlePubMedGoogle Scholar
  15. Uganda Bureau of Statistics (UBOS) and ICF International Inc. 2012. Uganda Demographic and Health Survey. Kampala, UBOS and Calverton, Maryland: ICF International Inc; 2011.Google Scholar
  16. Lunyera J, Mohottige D, Isenburg MV, Jeuland M, Patel UD, Stanifer JW. CKD of uncertain etiology: a systematic review. Clin J Am Soc Nephrol. 2015. pii: CJN.07500715 [Epub ahead of print].Google Scholar
  17. Konta T, Hao Z, Takasaki S. Clinical utility of trace proteinuria for microalbuminuria screening in the general population. Clin Exp Nephrol. 2007;11(1):51–5 (Epub 2007 Mar 28).View ArticlePubMedGoogle Scholar
  18. de Jong PE, Brenner BM. From secondary to primary prevention of progressive renal disease: the case for screening for albuminuria. Kidney Int. 2004;66:2109–18.View ArticlePubMedGoogle Scholar
  19. Van der Walt I, Swanepoel CR, Mahala B, Meyers AM. Important complications of chronic kidney disease. S Afr Med J. 2015;105:2682. doi:https://doi.org/10.7196/samj.9536.PubMedGoogle Scholar
  20. Katende D, Mutungi G, Baisley K, et al. Readiness of Ugandan health services for the management of outpatients with chronic diseases. Trop Med Int Health. 2015;20(10):1385–95.View ArticlePubMedGoogle Scholar
  21. Garcia-Garcia G, Marquez-Magaña I, Renoirte-Lopez K, et al. Screening for kidney disease on World Kidney Day in Jalisco, Mexico. J Nephrol. 2010;23(02):224–30.PubMedGoogle Scholar
  22. White SL, Yu R, Craig JC, Polkinghorne KR, Atkins RC, Chadban SJ. Diagnostic accuracy of urine dipsticks for detection of albuminuria in the general community. Am J Kidney Dis. 2011;58(1):19–28.View ArticlePubMedGoogle Scholar
  23. Puzantian HV, Townsend RR. Understanding kidney function assessment: the basics and advances. J Am Assoc Nurse Pract. 2013;25(7):334–41.PubMedGoogle Scholar
  24. Kalyesubula R, Odiit A, Wekesa C, Katali E, Sekasanvu E, Kotanko P, Carter M. A time to improve kidney care and awareness in Uganda. Dialysis Times. 2012;19(2):1–4.Google Scholar
  25. Mehta RL, Cerdá J, Burdmann EA, Tonelli M, et al. International Society of Nephrology’s 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology. Lancet. 2015;385(9987):2616–43.View ArticlePubMedGoogle Scholar
  26. Coresh J, Byrd-Holt D, Astor BC, Briggs JP, Eggers PW, Lacher DA, Hostetter TH. Chronic kidney disease awareness, prevalence, and trends among US adults, 1999 to 2000. J Am Soc Nephrol. 2005;16:180–8.View ArticlePubMedGoogle Scholar
  27. Minutolo R, De Nicola L, Mazzaglia G, Postorino M, Cricelli C, Mantovani LG, Conte G, Cianciaruso B. Detection and awareness of moderate to advanced CKD by primary care practitioners: a cross-sectional study from Italy. Am J Kidney Dis. 2008;52:444–53.View ArticlePubMedGoogle Scholar
  28. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(supp 1):S1–266.Google Scholar
  29. Atkins RC. The changing patterns of chronic kidney disease: the need to develop strategies for prevention relevant to different regions and countries. Kidney Int Suppl. 2005;68(suppl 98):S83–8.View ArticleGoogle Scholar

Copyright

© Lunyera et al. 2016

Advertisement